Key result
Clopidogrel monotherapy showed a non-significant 17.3% reduction in myocardial infarction risk compared to aspirin monotherapy, with comparable safety regarding serious bleeding in patients with chronic coronary syndrome.
Why the study?
Evidence-based support was needed regarding the comparative efficacy and safety of clopidogrel, aspirin, and their combination for long-term antiplatelet therapy in chronic coronary syndrome.
Does clopidogrel monotherapy or clopidogrel combined with aspirin improve efficacy and safety outcomes compared to aspirin monotherapy in patients with chronic coronary syndrome?
Meta-Analysis
Yes
Does clopidogrel monotherapy or clopidogrel combined with aspirin improve efficacy and safety outcomes compared to aspirin monotherapy in patients with chronic coronary syndrome?
In patients with chronic coronary syndrome, clopidogrel is a reasonable and safe alternative to aspirin, while dual antiplatelet therapy may offer modest symptom improvements but should be individualized due to bleeding risks.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Does not establish clopidogrel superiority over aspirin for MI prevention; leaves open optimal monotherapy choice in chronic coronary syndrome.
Objective To systematically evaluate and compare the efficacy and safety of clopidogrel and aspirin, as well as their combination, in patients with chronic coronary syndrome (CCS), and to provide evidence-based support for long-term antiplatelet therapy in stable coronary artery disease. Methods A comprehensive literature search was conducted in CNKI, WanFang, PubMed, Web of Science, and Embase databases from January 1990 to July 2025. Randomized controlled trials comparing clopidogrel and aspirin as monotherapy or in combination in patients with CCS were included. Relative risk (RR) or mean difference (MD) with 95% confidence intervals (CI) were pooled using fixed- or random-effects models according to heterogeneity. Publication bias and sensitivity analyses were performed where appropriate. Results A total of 24 studies involving patients with chronic coronary syndrome were included. Compared with aspirin monotherapy, clopidogrel monotherapy was associated with a numerically lower incidence of myocardial infarction, although the difference was not statistically significant. No significant difference in the risk of serious bleeding events was observed between clopidogrel and aspirin. Combination therapy with clopidogrel and aspirin was associated with a higher treatment response rate and a tendency toward reduced angina frequency compared with aspirin alone; however, substantial heterogeneity was present, and the observed benefits were mainly confined to subjective or semi-quantitative outcomes. The incidence of common adverse reactions, including gastrointestinal discomfort, dizziness, and headache, was numerically lower in the combination therapy group, but these differences did not reach statistical significance. Conclusion In patients with chronic coronary syndrome, clopidogrel represents a reasonable alternative to aspirin for long-term antiplatelet therapy, with comparable efficacy and safety. Combination therapy with clopidogrel and aspirin may offer modest improvements in symptom-related outcomes; however, these findings should be interpreted cautiously due to heterogeneity, potential publication bias, and the subjective nature of some endpoints. Individualized antiplatelet strategies based on ischemic and bleeding risk remain essential in stable coronary artery disease. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420251108327 .
Wei et al. (2026) conducted a meta-analysis in Adults with chronic coronary syndrome (stable coronary heart disease) with disease duration exceeding 1 year. Clopidogrel monotherapy, Clopidogrel plus aspirin combination therapy vs. Aspirin monotherapy was evaluated on Myocardial infarction incidence for monotherapy comparison; treatment success rate and angina frequency for combination therapy comparison; serious bleeding events (BARC ≥ 3) for safety (RR 0.827 for MI with clopidogrel vs aspirin monotherapy, 95% CI 0.660–1.036). Clopidogrel monotherapy showed a non-significant 17.3% reduction in myocardial infarction risk compared to aspirin monotherapy, with comparable safety regarding serious bleeding in patients with chronic coronary syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: